Neumora Therapeutics, Inc. NMRA
At closeNov 6, 2026, 6:12 PM EST
After hours · Nov 6, 6:12 PM ET
- YTD
- -71.88%
- 1 year
- -80.49%
- Market cap
- 94.57M
- EPS (ttm)
- -1.23
- Shares out
- 161.56M
- Forward P/E
- -1.01
- YTD return
- -71.88%
- 1-year return
- -80.49%
- Volume
- 970.97K
- Avg volume
- 1.65M
- Open
- 0.5699
- Previous close
- 0.487
- Day's range
- 0.4703 – 0.5699
- 52-week range
- 0.315 – 3.65
- Analysts
- Buy
- Price target
- 11.77 (+2237.9%)
- Earnings date
- Aug 6, 2024
2Y -12.2067 (-96.04%)
Key statistics
- Enterprise value
- -88.14M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -113.14M
- Total cash
- 341.31M
- Total debt
- 2.75M
- Return on equity
- -70.48%
- Short % of float
- 13.11%
- 50-day average
- 4.09
- 200-day average
- 9.57
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 11.77
- Target (high)
- 30.00
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -0.44226.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.38 | -0.45 | -0.07 | -18.42% |
| Aug 6, 2024 | Jun 1, 2024 | -0.37 | — | — | — |
| Aug 6, 2024 | Jun 1, 2024 | -0.37 | -0.37 | 0.00 | 0.00% |
| May 7, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -0.35 | -0.34 | +0.01 | +2.86% |
| Mar 7, 2024 | Dec 1, 2023 | -0.65 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 14, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 6, 2025 | B of A Securities | main | Buy | Buy |
| Jan 3, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 2, 2025 | Needham | reit | Buy | Buy |
| Dec 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 22, 2024 | RBC Capital | reit | Outperform | Outperform |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- neumoratx.com
News
12 Health Care Stocks Moving In Friday's After-Market Session 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's After-Market Session 
12 Health Care Stocks Moving In Friday's After-Market Session - 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate 
Why Is BioAge Labs Stock Sinking Friday? 
Neumora Therapeutics Reported Favorable Preclinical Toxicology Results From NMRA-215, An Oral NLRP3 Inhibitor In Development For Obesity And Cardiometabolic Disease; Plans To Submit An IND Application In Q4 Of 2026 
RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5
Your note
Sign in to keep a note on NMRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AURORA DALJIT SINGH | Officer | Sale | Feb 17, 2025 | 203,638 |
| BERNS PAUL L | Chief Executive Officer | Sale | Feb 17, 2025 | 7,804,300 |
| BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 12, 2024 | 31,979,900 |
| FUST MATTHEW K. | Director | Conversion of Exercise of derivative security | Oct 17, 2024 | 20,100 |
| HALAWA ALAA A. | Director | Stock Award(Grant) | Jun 12, 2024 | 20,100 |
| HO MAYKIN | Director | Stock Award(Grant) | Jun 12, 2024 | 20,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 4.85% | 7,838,577 | 12.23M | Dec 30, 2024 |
| Blackrock Inc. | 4.40% | 7,106,996 | 11.09M | Dec 30, 2024 |
| Softbank Group Corporation | 4.05% | 6,541,190 | 10.20M | Dec 30, 2024 |
| T. Rowe Price Investment Management, Inc. | 3.10% | 5,002,799 | 7.80M | Dec 30, 2024 |
| Vanguard Group Inc | 2.83% | 4,572,308 | 7.13M | Dec 30, 2024 |
| MIC Capital Management UK LLP | 2.76% | 4,460,700 | 6.96M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.48% | 2,393,040 | 3.73M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.41% | 2,271,546 | 3.54M | Dec 30, 2024 |
| Price (T.Rowe) Small-Cap Value Fund | 0.80% | 1,295,999 | 2.02M | Dec 30, 2024 |
| Vanguard Extended Market Index Fund | 0.77% | 1,251,605 | 1.95M | Sep 29, 2024 |
| Price (T.Rowe) Small Cap Stock Fund | 0.60% | 965,141 | 1.51M | Dec 30, 2024 |
| Fidelity Small Cap Index Fund | 0.53% | 860,150 | 1.34M | Oct 30, 2024 |